CMV IE-1 (213–225)
CMV pp65 (415-429) (HLA-B7) is a CEF control peptide that is derived from the Cytomegalovirus (CMV).
Catalogue number crb1001668 Molecular Weight 1516.8 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
La Rosa amd Diamond (2012). The immune response to human CMV. Future Virol. PMID: 23308079
Zhang et al (2012). How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses. PMID: 23202497
Liechti and Roederer (2019). OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. PMID: 31334913
Manufactured in: United Kingdom
CMV pp65 (415-429) (HLA-B7) is a CEF (cytomegalovirus, Epstein-Barr virus, and influenza virus) control peptide that is derived from the Cytomegalovirus (CMV). CMV is capable of infecting a wide range of human cell types, where the body’s primary immune response to CMV is innate, and relies on inflammatory cytokines and costimulatory molecules in order to control the spread of the virus. CMV pp65 (415-429) (HLA-B7) is defined as a CEF control peptide due to its antigenic properties. Clinically, these peptides are suitable epitopes for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B7 refers to the cell HLA type that this peptide acts on.